0001104659-24-046096.txt : 20240411 0001104659-24-046096.hdr.sgml : 20240411 20240411080310 ACCESSION NUMBER: 0001104659-24-046096 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240410 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240411 DATE AS OF CHANGE: 20240411 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Black Diamond Therapeutics, Inc. CENTRAL INDEX KEY: 0001701541 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39200 FILM NUMBER: 24837166 BUSINESS ADDRESS: STREET 1: ONE MAIN STREET, 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-417-5868 MAIL ADDRESS: STREET 1: ONE MAIN STREET, 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Aset Therapeutics, Inc. DATE OF NAME CHANGE: 20170321 8-K 1 tm2411574d1_8k.htm FORM 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 10, 2024

BLACK DIAMOND THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)


Delaware	001-39200	81-4254660
(State or other jurisdiction	(Commission	(I.R.S. Employer
of incorporation)	File Number)	Identification No.)

One Main Street, 14^th Floor
Cambridge, Massachusetts		02142
(Address of Principal Executive Offices)		(Zip Code)

(617) 252-0848

(Registrant’s telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	BDTX	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Resignation of Alexander Mayweg, Ph.D.

On April 10, 2024, Alexander Mayweg, Ph.D. resigned from the Board of Directors (the “Board”) of Black Diamond Therapeutics, Inc. (the “Company”). Dr. Mayweg’s decision to resign from the Board was not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company.

Resignation of Wendy L. Dixon, Ph.D.

On April 10, 2024, Wendy L. Dixon, Ph.D. resigned from the Board and all committees thereof, including her position as Chair of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”). Dr. Dixon’s decision to resign from the Board was not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company.

Appointment of Prakash Raman, Ph.D. and Shannon Campbell

On April 10, 2024 (the “Appointment Date”), upon the recommendation of the Nominating and Corporate Governance Committee, the Board appointed (i) Prakash Raman, Ph.D. to serve on the Board as a Class I director to hold office until the Company’s annual meeting of stockholders in 2024 or until his earlier death, resignation or removal, and (ii) Shannon Campbell to serve on the Board as a Class III director to hold office until the Company’s annual meeting of stockholders in 2026 or until her earlier death, resignation or removal. In addition, effective as of the Appointment Date, the Board appointed (i) Dr. Raman to serve as a member of the Nominating and Corporate Governance Committee and Audit Committee of the Board, and (ii) Ms. Campbell to serve as a member of the Compensation Committee of the Board, until their respective successors are elected and qualified, or until their earlier death, resignation or removal, or until otherwise determined by the Board.

In connection with Dr. Raman and Ms. Campbell’s appointment to the Board, the Board determined that each of Dr. Raman and Ms. Campbell is independent under the applicable listing standards of Nasdaq.

As non-employee directors, Dr. Raman and Ms. Campbell will receive compensation, including an initial equity award for their Board service in accordance with the Company’s Fifth Amended and Restated Non-Employee Director Compensation Policy. Dr. Raman and Ms. Campbell are not parties to any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K, and there are no arrangements or understandings between Dr. Raman and Ms. Campbell and any other persons pursuant to which they were selected as directors. In addition, Dr. Raman and Ms. Campbell will each enter into an indemnification agreement with the Company consistent with the form of indemnification agreement entered into between the Company and its existing non-employee directors.

Item 7.01 Regulation FD Disclosure.

On April 11, 2024, the Company issued a press release entitled “Black Diamond Therapeutics Announces Changes to Board of Directors.” A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished under this Item 7.01, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release issued by Black Diamond Therapeutics, Inc., dated April 11, 2024, furnished herewith.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BLACK DIAMOND THERAPEUTICS, INC.

Date: April 11, 2024	By:	/s/ Brent Hatzis-Schoch
	Name:	Brent Hatzis-Schoch
	Title:	Chief Operating Officer and General Counsel

EX-99.1 2 tm2411574d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

Black Diamond Therapeutics Announces Changes to Board of Directors

CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) – Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancers, today announced that industry veterans Shannon Campbell and Prakash Raman, Ph.D., have been appointed to the Company’s Board of Directors. The Company also announced that Wendy Dixon, Ph.D., and Alex Mayweg, Ph.D., have stepped down as members of its Board of Directors. These changes became effective as of April 10, 2024.

“On behalf of the board, I am excited to welcome Shannon and Prakash, both seasoned executives who bring deep and highly relevant oncology expertise to our board as we advance BDTX-1535, a potential first and best-in-class fourth-generation EGFR inhibitor,” said Mark Velleca, M.D., Ph.D., Chief Executive Officer of Black Diamond Therapeutics. “I would also like to thank Alex for his many years of support for Black Diamond and Wendy for her important contributions as a board member.”

"I am thrilled to join the board of Black Diamond at this pivotal time as the Company advances BDTX-1535 through Phase 2 development, and am excited by its potential to address the substantial and growing unmet need for patients with NSCLC in both front-line and later lines of therapy,” said Ms. Campbell.

Shannon Campbell currently serves as the Executive Vice President and Chief Commercial Officer at Merus, a clinical-stage oncology company developing multispecific antibody therapeutics, where she is responsible for Merus’s global commercialization strategy and activity. With over 30 years of biopharmaceutical experience, Ms. Campbell possesses deep expertise in commercializing transformative medicines globally. Before joining Merus, Ms. Campbell led the U.S. Solid Tumor Franchise at Novartis, and previously led the US Oncology Business Unit at Bayer HealthCare Pharmaceuticals. Earlier in her career she held positions of increasing responsibility at Abbott Labs and Pharmacia heritage companies. Ms. Campbell holds a Bachelor of Science degree from Ithaca College and has completed leadership, strategy, and finance programs at the University of Michigan Ross School of Business, IMD, Harvard Business School, and The Wharton School, University of Pennsylvania.

"I am extremely impressed by Black Diamond’s development progress with both BDTX-1535 and BDTX-4933, and look forward to partnering with the board and the management team to maximize the potential of these novel compounds,” said Dr. Raman.

Prakash Raman, Ph.D., has over two decades of biopharmaceutical business development and executive leadership experience, blending his scientific background, program and portfolio management and strong business development experience. He currently serves as Chief Executive Officer of a stealth biopharma company working on novel protein therapeutics in Oncology and Immunology. Previously, he was President and Chief Executive Officer of Ribon Therapeutics, a biopharmaceutical company focused on small molecule drugs for Oncology and Immunology. Prior to joining Ribon, he served as Senior Partner, Chief Business Development Officer at Flagship Pioneering. Before Flagship, he was Vice President, Global Head of Novartis Institutes for Biomedical Research Business Development and Licensing. Dr. Raman was instrumental in forging key collaborations in immuno-oncology, executing many out-licensing opportunities, guiding acquisitions, and led cross-functional drug discovery and early development project teams. Dr. Raman’s previous roles include Senior Scientist at Millennium Pharmaceuticals and post-doctoral fellow at The Scripps Research Institute. He completed his undergraduate work at the Indian Institute of Technology, Bombay, and received his Ph.D. in Organic and Medicinal Chemistry from the University of Wisconsin-Madison.

About Black Diamond Therapeutics

Black Diamond Therapeutics is a clinical-stage oncology company focused on the development of MasterKey therapies that address families of oncogenic mutations in clinically validated targets. The Company’s MasterKey therapies are designed to address broad genetically defined patient populations, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat CNS disease. The Company is advancing two clinical-stage programs: BDTX-1535, a brain-penetrant fourth-generation EGFR MasterKey inhibitor targeting EGFR mutant NSCLC and GBM, and BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. For more information, please visit www.blackdiamondtherapeutics.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the continued development and advancement of BDTX-1535 and BDTX-4933, and the potential of BDTX-1535 to benefit patients with NSCLC. Any forward-looking statements in this statement are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include those risks and uncertainties set forth in its Annual Report on Form 10-K for the year ended December 31, 2023, filed with the United States Securities and Exchange Commission and in its subsequent filings filed with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Contacts

For Investors:

Mario Corso, Head of Investor Relations, Black Diamond Therapeutics

mcorso@bdtx.com

For Media:

media@bdtx.com

EX-101.SCH 3 bdtx-20240410.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 bdtx-20240410_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 bdtx-20240410_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2411574d1_ex99-1img001.jpg GRAPHIC begin 644 tm2411574d1_ex99-1img001.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT

Cover	Apr. 10, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Apr. 10, 2024
Entity File Number	001-39200
Entity Registrant Name	BLACK DIAMOND THERAPEUTICS, INC.
Entity Central Index Key	0001701541
Entity Tax Identification Number	81-4254660
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	One Main Street, 14th Floor
Entity Address, City or Town	Cambridge
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02142
City Area Code	617
Local Phone Number	252-0848
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	BDTX
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( &1 BU@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !D0(M8)\0AI^X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M3L,P#(9?!>7>.FD'AZC+96BG(2$Q"<0M2KPMHFFCQ*C=VY.6K1."!^ 8^\_G MSY(;$Z3I(S['/F DA^EN]&V7I EK=B(*$B"9$WJ=RISHGW-^RU3%JU7!5X40>U%)7DM^_SZY_O"["?O>NH/[ MQ\970=7 K[M07U!+ P04 " !D0(M8F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M &1 BUC:(*BLBP0 $,1 8 >&PO=V]R:W-H965T&UL MC9A1<^(V$,??^RDT;J?3SI!@.4!("LPX0'I,$L(%TNNTTP=A"]#$MGR2'))O MWY4A-G=GUN0A6,;[]T^[JUV)WE:J%[WAW)"W.$ITW]D8DUXWFSK8\)CIS$PD$CY31&=QS-3[ M#8_DMN]0Y^/&DUAOC+W1'/12MN9S;I[3F8)1LU )1WWAM M:Y _\9?@6WUP3>Q4EE*^V,$D[#NN)>(1#XR58/#QRH<\BJP2<'S=BSK%.ZWA MX?6'^FT^>9C,DFD^E-$7$9I-W^DZ).0KED7F26X_\?V$JUO MS9M 4&!X!8:7ZUU@&.1??ZF-@D#]5T6T4VA5*]CLO=8I"WC?@?347+UR9_#K MS[3C_H'P711\%YCZ8"2##'+1D,5[RJO@[X&B?YHP95T*&9)R$!)*OTB^X4I%&=7G4*= ZJ. X,<*\DUL1 M<3+-XF5U;N,:KDO/+JZ@K"$\EP7/Y2D\3WPM;&:#SZ8LKG04KG-S[P_OR&CB M/SQ.1V3Q:?SDS\;/B\EPWB"3Z? <0>T6J-U34(<06,4B,DE"_D;N^'L5+*[D M@@DVHR7!*L?B+P]P"M'Z:KH ,U"&V9#50G*16&778%BA;U'["'=@1. M7)%_7NX(N0S)5]%$E0[%==\\#&TLE%0O-)_ MCS:3VL":_D>DQ_,05W0]VO(PMK)Y4+SFYS'T80=Y' 47Z-!+#*1L%12O\_D6-B-?VSMQNJXL1ER)8.OX MN%H=B1^N5T?FE7W PROU#V03K3,@JP.LD:T%+'N AQ?LA3"P*Y(K0KW?EK^3 M.0\RR+?*_EZC9/-3VJ(O@Y<&^<4]MQV?I$R15Q9EG*0P7[UA"N4^.!K@57NA M6&CS;_X>+V5E]M4(W(P6?V,D9<7W\.K\X3(R?@LV+%GSH[NY&J&I/Q_YGS&F MLM1[)Y7Z<&ULW5=M:]LP$/XK M0C]@;F)JXI$8MD!AL(U"\V%?E5AV!'KQ9+ES^NNGLVPG:75EW8>QS:')W3VZ MNT=W)YFN6W>2_.'(N2.]DKK=T*-SS?LD:0]'KEC[SC1<>Z0R5C'G55LG;6,Y M*UMP4C)9WMQDB6)"TV*M.W6G7$L.IM-N0V]H4JPKH\^6E :#7\H4)X],;NB6 M2;&W8EC+E)"G8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP'.,HH8T%8Q(RA._]N/P9 M,&FM5X64,\$E#89BW3#GN-5W7AD6#\87$!GEW:GQ#&O+3HOE+3T[##\^R=[8 MDMLYS8).IF(M>05TK*B/\.M,DP#HG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J* MW5B'_2^FO-CT1=X=-8T\O1!BEHK'O;^RPF+-9O\R-%8\>2SP:0)P:?EA6;/CO9NFJ:]PSLM_D/.?K7/--;=,7I+VH_\W5_DMC)/Q]%PZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/ M[I_X3O,\3;,,J^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*P MG>*3B.T4KS4@\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0ERHY M_U=3_ 102P,$% @ 9$"+6)>*NQS $P( L !?3T\ M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5* M(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'B4?'D78FYJD6:>IK&HP=MX1PT$G53$ MWHI"/J:Q8;!EK '$NW2:9;/46PQFN1BUMIS> A(H!"DHV1%[A$O\G7D(GP&LK\,S4-AB.G8RF2&]B M]#V,YU#BG/]3(U45%K"FHO409.B1P74&0ZRQB28)UD-N5G0&[O+H YMRR"9J MZJ8IGJ,.>%,.]D9/)508H'Q3F:B\]E-L.>F.7F=Z_S!YU!Y:YU;*O8=7LN48 MY0]02P,$% @ 9$"+6"0>FZ*M ^ $ !H !X;"]?+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J M%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I M2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC M":[?#'!X=/X!4$L#!!0 ( &1 BUAED'F2&0$ ,\# 3 6T-O;G1E M;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=: MTMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E) M_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I* M&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7H MK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC* M30H1.;$$?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^D&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( M &1 BUC:(*BLBP0 $,1 8 " @0T( !X;"]W;W)K&PO&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 M " !D0(M899!YDAD! #/ P $P @ '8$@ 6T-O;G1E C;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" B% ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://blackdiamondtherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports bdtx-20240410.xsd bdtx-20240410_lab.xml bdtx-20240410_pre.xml tm2411574d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2411574d1_8k.htm": { "nsprefix": "BDTX", "nsuri": "http://blackdiamondtherapeutics.com/20240410", "dts": { "schema": { "local": [ "bdtx-20240410.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "bdtx-20240410_lab.xml" ] }, "presentationLink": { "local": [ "bdtx-20240410_pre.xml" ] }, "inline": { "local": [ "tm2411574d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://blackdiamondtherapeutics.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-04-10", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2411574d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-04-10", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2411574d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001104659-24-046096-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-046096-xbrl.zip M4$L#!!0 ( &1 BUA:(2#:. , !,, 1 8F1T>"TR,#(T,#0Q,"YX M],_T'U:\8VAB8M!)+)I>G0(4T"N34O'2$+T"!+CB0'TZ^O MY!L7 P7:^DG>/>?LKK0KNWD:!Q2\82$)9RW+]BW;; M JXC9CX7#]UVH3M2*I0-UYU,)@[C;W#"Q5@Z MB ?;"?845)$LU"IQ)7NVHU\3B0KR 3P[G'R*N^1YB-GGJ -K+^@)5K]$_1O_ MUTOWH/IC'*O@_*A_%[RZ4S24T\/*M^DX.JO?/LF[Z_,T9%.B$0X@T(?!9,LR M]67E36H.%T.W6JEX[O-UIY?@K!38B"EAXU5PKUZONXDWAY:0<5_07+KF&G?.BFS@4H60D]2J$DA_IX"20-E/1#/' E@*509JXS+(5M,0RY70U+5 .+^\?RZP?0K1V"

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end XML 18 tm2411574d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001701541 2024-04-10 2024-04-10 iso4217:USD shares iso4217:USD shares false 0001701541 8-K 2024-04-10 BLACK DIAMOND THERAPEUTICS, INC. DE 001-39200 81-4254660 One Main Street, 14th Floor Cambridge MA 02142 617 252-0848 false false false false Common Stock, $0.0001 par value per share BDTX NASDAQ true false